Resmetirom, now Rezdiffra, is 1st therapy approved for NASH in US
The U.S. Food and Drug Administration (FDA) has approved Rezdiffra (resmetirom) for the treatment of people with noncirrhotic nonalcoholic steatohepatitis (NASH) — a severe type…
News
Atea’s antiviral treatment combo works for 98% of HCV patients
Note: This story was updated Aug. 22, 2024, to clarify the timeline detailing the results of treatment. Atea Pharmaceuticals’ once-daily oral antiviral treatment for…
FDA approves Mirum’s Livmarli for PFIC patients ages 5 and older
The U.S. Food and Drug Administration (FDA) has approved Mirum Pharmaceuticals’ Livmarli (maralixibat) to reduce pruritus, or itching, in adults and children, 5 years…
Phase 2 study of LB-P8 for PSC nets FDA clearance
LISCure Biosciences will launch a Phase 2 trial in the United States to evaluate the safety and effectiveness of LB-P8, its live bacterium candidate…
Sodium 4-phenylbutyrate delayed transplant need in 2 PFIC2 children
Treatment with an oral medication called sodium 4-phenylbutyrate — approved to treat diseases in which the body fails to remove a waste called ammonia…
Small amounts of alcohol deemed OK in early steatotic liver disease
Drinking a small amount of alcohol each day did not raise the mortality risk among people in the early stages of steatotic liver disease…
Livmarli’s long-term benefits in Alagille extend beyond itch: Study
Up to six years of treatment with Livmarli (maralixibat), which is approved for reducing itch, or pruritus, in Alagille syndrome, prolonged survival and…
Many viruses behind 2022 outbreak of hepatitis in children: Study
A global outbreak of severe hepatitis in children just after COVID-19 restrictions were lifted could have been caused by infections with multiple viruses at…
Seladelpar found to reduce disease activity, itch in PBC patients in trial
Daily treatment with seladelpar, CymaBay Therapeutics’ investigational oral candidate for people with primary biliary cholangitis (PBC), was shown to normalize liver biomarkers and…
Probiotics may help women with ICP, but risks not yet known
Women with intrahepatic cholestasis of pregnancy (ICP) show lesser diversity across their gut bacteria than do other pregnant women, a study reports. Its findings…
